GlassScriptPhysician profile
Ghiath Mahmaljy
NPI 1972574432
$8,223.44
in general payments reported to CMS, 2019-2025
31 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $1,502 · 2021: $1,554 · 2022: $1,319 · 2023: $905 · 2024: $725 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Gift: $59.40 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.57 |
| Gift | $59.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,864.48 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Sanofi-Aventis U.S. LLC | $1,113.27 | 2019-2024 | |
| Lilly USA, LLC | $861.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $418.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.93 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $354.23 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $306.30 | 2023-2025 | Minimed 780g |
| Amgen INC. | $258.46 | 2019-2025 | Evenity |
| Astrazeneca Pharmaceuticals LP | $245.35 | 2019-2024 | Farxiga |
| Dexcom, INC. | $173.40 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $135.49 | 2020-2025 | Gvoke Hypopen |
| Abbvie INC. | $129.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $118.32 | 2019-2020 | |
| Amarin Pharma, INC. | $106.14 | 2019-2022 | |
| Genzyme Corporation | $105.00 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $99.28 | 2022-2025 | Korlym |
| Shire North American Group INC | $70.88 | 2019 | |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Esperion Therapeutics, INC. | $59.30 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.12 | 2019 | |
| Insulet Corporation | $46.57 | 2021-2025 | Omnipod |
| Nevro Corp. | $44.90 | 2022-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $38.16 | 2022 | |
| Pfizer INC. | $31.34 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $22.56 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $20.39 | 2025 | Twiist |
| Ibsa Pharma INC. | $19.57 | 2020 | |
| Acella Pharmaceuticals, LLC | $15.97 | 2025 | NP Thyroid 60 |
| Cequr Corporation | $15.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2021 | |
| Tandem Diabetes Care, INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghiath Mahmaljy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.